Literature DB >> 12460919

Missense mutations of the BRAF gene in human lung adenocarcinoma.

Katsuhiko Naoki1, Tzu-Hsiu Chen, William G Richards, David J Sugarbaker, Matthew Meyerson.   

Abstract

Mutations of the BRAF protein serine/threonine kinase gene have recently been identified in a variety of human cancers, most notably melanomas. We sought to determine the frequency of BRAF mutations in human lung cancer pathogenesis. Analysis of BRAF sequence from 127 primary human lung adenocarcinomas revealed mutations in two tumor specimens, one in exon 11 (G465V), and a second in exon 15 (L596R). These specimens belong to the same adenocarcinoma subgroup as defined by clustering of gene expression data. BRAF may provide a target for anticancer chemotherapy in a subset of lung adenocarcinoma patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12460919

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  97 in total

1.  Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials.

Authors:  A Black; D Morris
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

Review 2.  NF-κB addiction and its role in cancer: 'one size does not fit all'.

Authors:  M M Chaturvedi; B Sung; V R Yadav; R Kannappan; B B Aggarwal
Journal:  Oncogene       Date:  2010-12-20       Impact factor: 9.867

3.  Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy.

Authors:  Bingxue Shang; Gaochuan Zhang; Yanyan Pan; Quansheng Zhou
Journal:  Cancer Microenviron       Date:  2012-05-17

4.  Development and applications of a BRAF oligonucleotide microarray.

Authors:  Il-Jin Kim; Hio Chung Kang; Sang Geun Jang; Sun-A Ahn; Hyun-Ju Yoon; Jae-Gahb Park
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

Review 5.  New treatment options for lung adenocarcinoma--in view of molecular background.

Authors:  Nora Bittner; Gyula Ostoros; Lajos Géczi
Journal:  Pathol Oncol Res       Date:  2013-12-05       Impact factor: 3.201

Review 6.  Molecular determinants of lung cancer metastasis to the central nervous system.

Authors:  Timothy G Whitsett; Landon J Inge; Harshil D Dhruv; Philip Y Cheung; Glen J Weiss; Ross M Bremner; Jeffrey A Winkles; Nhan L Tran
Journal:  Transl Lung Cancer Res       Date:  2013-08

7.  p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.

Authors:  Stuart J Gallagher; John F Thompson; James Indsto; Lyndee L Scurr; Margaret Lett; Bo-Fu Gao; Ruth Dunleavey; Graham J Mann; Richard F Kefford; Helen Rizos
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

8.  Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.

Authors:  Frank Schönleben; Wanglong Qiu; John D Allendorf; John A Chabot; Helen E Remotti; Gloria H Su
Journal:  J Gastrointest Surg       Date:  2009-05-14       Impact factor: 3.452

9.  PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.

Authors:  Frank Schönleben; Wanglong Qiu; Helen E Remotti; Werner Hohenberger; Gloria H Su
Journal:  Langenbecks Arch Surg       Date:  2008-02-21       Impact factor: 3.445

10.  Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women.

Authors:  Yun-Hyun Cho; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Kyu-Rae Kim; Joo-Hyun Nam; Young-Tak Kim
Journal:  Yonsei Med J       Date:  2009-04-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.